Why Investors Love These Biotech's Stocks? - Cellectar Biosciences, Xenoport, Rexahn Pharma, and Tesaro
PR Newswire - Wed Jun 29, 6:45AM CDT
The Biotech industry has seen pressure with pricing, policies, and economic uncertainties, but still it continues to present a number of great trades. Stock-Callers.com reviews the performances of the following companies at yesterday's close and see if they are worthy of consideration: Cellectar Biosciences Inc. (NASDAQ: CLRB), Xenoport Inc. (NASDAQ: XNPT), Rexahn Pharmaceuticals Inc. (NYSE: RNN), and Tesaro Inc. (NASDAQ: TSRO). Learn more about these stocks and receive your complimentary trade alerts at:
CLRB: 3.31 (-0.10), RNN: 0.25 (-0.01), TSRO: 88.70 (-3.26), XNPT: 7.07 (+0.05)
Lifshitz & Miller Law Firm Announces Investigation of Exterran Corporation, inContact, Inc., LinkedIn Corporation, Mines Management, Inc., Rose Rock Midstream, L.P., STAAR Surgical Company, XenoPort, Inc. and Your Community Bankshares, Inc.
PR Newswire - Mon Jun 20, 11:52AM CDT
Exterran Corporation (EXTN) Lifshitz & Miller announces investigation on behalf of Exterran investors. Specifically, on April 26, 2016, Exterran announced it will restate its consolidated and combined financial statements for 2015 and expects to delay the filing of its Form 10-Q for the quarter ended March 31, 2016.
EXTN: 13.58 (+0.54), LNKD: 190.44 (+0.24), SAAS: 13.88 (+0.04), STAA: 5.99 (+0.23), YCB: 37.15 (+0.48), RRMS: 26.70 (+0.99), MGN: 1.33 (+0.11), XNPT: 7.07 (+0.05)
Arbor Pharmaceuticals and XenoPort Announce the Expiration of the HSR Act Waiting Period
BusinessWire - Thu Jun 16, 5:30AM CDT
Arbor Pharmaceuticals, LLC ("Arbor"
XNPT: 7.07 (+0.05)
Surging Earnings Estimates Signal Good News for Xenoport (XNPT)
Zacks Equity Research - Zacks Investment Research - Mon Jun 06, 7:55AM CDT
Xenoport (XNPT) could be good choice for investors as it is seeing decent short-term momentum and positive earnings estimate revisions.
XNPT: 7.07 (+0.05)